March 22nd 2023
Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Trekking Through the Latest Updates for ROS1-Targeted Therapies
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
View More
Navigating the Latest Data on NTRK-Targeted Therapies
View More
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
View More
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
View More
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
View More
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
View More
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
View More
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
View More
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
View More
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
View More
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
View More
Advances In™: The Role of NRG1 Fusions Across Tumor Types
View More
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
View More
Sintilimab Plus Bevacizumab Biosimilar Injection Yields Improved PFS in nsqNSCLC
November 22nd 2021Patients with EGFR-mutated non-squamous non–small cell lung cancer who progressed following EGFR-TKI therapy experienced a progression-free survival benefit following treatment with sintilimab plus a bevacizumab biosimilar injection and chemotherapy.
FDA Grants Fast Track Designation to Bemcentinib for STK11-Mutated Advanced/Metastatic NSCLC
November 9th 2021The FDA granted Fast Track Designation to bemcentinib combined with a PD-L1 agent to treat patients with STK11 altered advanced/metastatic non–small cell lung cancer without actionable mutations.
Neoadjuvant Nivolumab/Chemo Combo Yields Significant EFS Improvement in Resectable NSCLC
November 8th 2021Findings from the CheckMate 816 trial indicated that the combination of nivolumab and chemotherapy as neoadjuvant therapy resulted in a significant event-free survival benefit for patients with resectable non–small cell lung cancer.
Lyudmila Bazhenova, MD, Discusses the Outcomes With Immunotherapy in Wild-Type vs EGFR Exon 20 NSCLC
October 24th 2021CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to discuss differences in outcomes with immunotherapy agents in patients with wild-type and EGFR exon 20 insertion–positive non–small cell lung cancer.
Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC
October 18th 2021Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor.
SABR Non-Inferior to VATS L-MLND in Operable Stage I Non–Small Cell Lung Cancer
October 14th 2021Treatment with stereotactic ablative radiotherapy yielded non-inferior long-term survival compared with video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection in operable stage IA non–small cell lung cancer.
Ensartinib Yields Superior Efficacy Over Crizotinib for ALK-Positive Non–Small Cell Lung Cancer
September 23rd 2021Results from the phase 3 eXalt3 study indicated that ensartinib led to a longer progression-free survival and intracranial response rate compared with crizotinib for patients with ALK-positive non-small cell lung cancer.
Durvalumab Demonstrates Real-World PFS Benefit In Unresectable Stage III NSCLC
September 22nd 2021Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.
Blood-Based Tumor Mutational Burden Does Not Predict Benefit of Atezolizumab for NSCLC
September 21st 2021According to results from the Blood First Assay Screening Trial, blood-based tumor mutational burden did not predict a benefit of atezolizumab over chemotherapy for patients with non-small cell lung cancer.
Treatment With Adjuvant Atezolizumab Yields Improved Outcomes in Stage II-IIIA PD-L1–Positive NSCLC
September 20th 2021Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.
Datopotamab Deruxtecan Shows Safe Antitumor Activity in Advanced NSCLC With Genomic Alterations
September 19th 2021The antibody drug conjugate, datopotamab deruxtecan, was safe in heavily pretreated patients who don’t have many treatment options after treatment with tyrosine kinase inhibitors and platinum-based chemotherapy.